Protagonist Therapeutics Inc (NASDAQ:PTGX)‘s stock had its “outperform” rating reissued by BMO Capital Markets in a report released on Friday. They currently have a $34.00 price target on the stock, up from their prior price target of $21.00. BMO Capital Markets’ price target would indicate a potential upside of 34.92% from the stock’s current price.

Several other equities research analysts have also commented on PTGX. Barclays PLC initiated coverage on Protagonist Therapeutics in a research report on Tuesday, September 6th. They set an “overweight” rating and a $18.00 target price on the stock. Leerink Swann initiated coverage on Protagonist Therapeutics in a research report on Tuesday, September 6th. They set an “outperform” rating and a $17.00 target price on the stock. Finally, Zacks Investment Research upgraded Protagonist Therapeutics from a “hold” rating to a “buy” rating and set a $22.00 target price on the stock in a research report on Wednesday, November 9th.

Protagonist Therapeutics (NASDAQ:PTGX) opened at 25.20 on Friday. The firm has a 50-day moving average price of $21.61 and a 200-day moving average price of $17.72. The company’s market capitalization is $414.82 million. Protagonist Therapeutics has a 1-year low of $10.02 and a 1-year high of $25.50.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its earnings results on Monday, November 14th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.58) by $0.29. During the same quarter in the prior year, the company posted ($12.79) earnings per share.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Credit Suisse AG purchased a new position in Protagonist Therapeutics during the third quarter worth $358,000. BVF Inc. IL purchased a new position in Protagonist Therapeutics during the third quarter worth $7,924,000. RA Capital Management LLC purchased a new position in Protagonist Therapeutics during the third quarter worth $15,941,000. Adage Capital Partners GP L.L.C. purchased a new position in Protagonist Therapeutics during the third quarter worth $33,408,000. Finally, Spark Investment Management LLC purchased a new position in Protagonist Therapeutics during the third quarter worth $889,000.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (Protagonist) is a clinical-stage biopharmaceutical company. The Company has a technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) to address unmet medical needs. Protagonist’s primary focus is on developing oral peptide drugs that specifically target biological pathways.

5 Day Chart for NASDAQ:PTGX

Receive News & Stock Ratings for Protagonist Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics Inc and related stocks with our FREE daily email newsletter.